All In Biotech

NDA 203496 · United Therap

Orenitram

Treprostinil Diolamine · Oral · Prostacycline Vasodilator

Orphan

Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Dec 20, 2013

Approved uses

3

Original approval plus efficacy supplements

Registered trials

8

6 Phase 3, 0 recruiting

FAERS reports

26,071

14,330 serious, 2,475 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2024.

Orenitram is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%). ( 1.1 ) 1.1 Pulmonary Arterial Hypertension Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%).

Mechanism: The major pharmacologic actions of treprostinil are direct vasodilation of pulmonary and systemic arterial vascular beds, inhibition of platelet aggregation, and inhibition of smooth muscle cell proliferation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • ORENITRAM · TREPROSTINIL DIOLAMINE EQ 5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ORENITRAM · TREPROSTINIL DIOLAMINE EQ 1MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ORENITRAM · TREPROSTINIL DIOLAMINE EQ 0.125MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ORENITRAM · TREPROSTINIL DIOLAMINE EQ 2.5MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • ORENITRAM · TREPROSTINIL DIOLAMINE EQ 0.25MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Treprostinil Diolamine" as an intervention, any sponsor and status, largest first.

All 8 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • headache5,649
  • diarrhoea4,908
  • dyspnoea4,709
  • nausea4,246
  • fatigue2,600
  • dizziness2,342
  • vomiting2,190
  • pain in extremity1,710
  • flushing1,707
  • hypotension1,516
  • malaise1,509
  • pain1,460

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20063
20071
20082
20098
201013
201123
201241
201343
2014386
20151,322
20161,826
20171,926
20182,198
20192,126
20202,001
20212,159
20222,381
20232,573
20242,241
20252,814
20261,983

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 8 on PubMed

Sponsor: United Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.